Industry Veteran Thomas Scientific Now Offering MicroGEM's Innovative Sal6830 Fast Saliva RT-PCR COVID-19 Test
Expanded partnership boosts MicroGEM's distribution capability
CHARLOTTESVILLE, Va., June 30, 2022 /PRNewswire/ -- MicroGEM, a leading innovator of person-portable diagnostic devices and nucleic acid extraction products, announced today that Thomas Scientific, the largest pure-play distributor of scientific products in the U.S., is now offering its customers the MicroGEM Sal6830 Point of Care PCR System and SARS-CoV-2 Saliva Test. Thomas Scientific already carries a suite of revolutionary MicroGEM life science products.
MicroGEM, a Virginia-based life sciences and molecular diagnostics company, develops innovative point-of-need diagnostic devices based on its revolutionary approach to sample preparation. The company recently received Emergency Use Authorization from the FDA for Sal6830, the world's first saliva PCR test to detect SARS-COV-2 at the point of care in under 30 minutes.
"The addition of the MicroGEM Sal6830 Point of Care PCR System to the Thomas Scientific portfolio is a logical extension of our existing single tube nucleic acid extraction technology, prepGEM, currently available through Thomas Scientific," said Geoffrey Stein, Director of Channel Partner Sales for MicroGEM. "Sal6830 captures whole virus, a key indicator of infectiousness, and offers non-invasive 'saliva sample to PCR result' in 27 minutes at the point of care. Together with Thomas Scientific, we can expand access to high-performance PCR saliva testing where COVID-19 decisions need to be made in real time."
"MicroGEM's forward-thinking, innovative approach has already been a tremendous asset to the Thomas portfolio, and the addition of the Sal6830 Point of Care PCR System and SARS-CoV-2 Saliva Test will only take this further," said Michael Brown, Sr. VP of Clinical Diagnostics and Bio Solutions at Thomas. "We are very excited to offer this product to address on-going needs for fast, high-quality testing."
The MicroGEM Sal6830 SARS-CoV-2 Saliva Test has been authorized for emergency use by the FDA under an EUA for use at the point of care in patient settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. MicroGEM is pursuing full FDA approval for the Sal6830.
Click here for more information about how MicroGEM and Thomas Scientific are providing fast, accurate PCR testing at the point of care.
Thomas Scientific provides the latest in supplies, equipment, and supply chain solutions to the scientific community – supporting all laboratory research, biopharmaceutical, medical device, clinical diagnostics, cleanroom, and other related end markets. We deliver individualized customer service, customized supply chain service solutions, and a comprehensive product portfolio at competitive prices. Whether you work in a lab setting or perform your testing in the field, Thomas Scientific has the products you need.
www.thomassci.com
Contact: Diane Skala, VP of Corporate and Supplier Marketing Services
856.832.3296
[email protected]
MicroGEM is democratizing molecular diagnostics by moving molecular techniques out of conventional, highly skilled laboratories to non-laboratory settings. The company's innovative enzymatic approach to nucleic acid extraction provides the foundation for efficient sample preparation suitable for PCR analysis. Recently awarded over $50 million by the National Institutes of Health, Rapid Acceleration of Diagnostics (RADx) initiative, MicroGEM has leveraged its RNA extraction capabilities to develop the MicroGEM Sal6830 Point of Care PCR System and SARS-CoV-2 Saliva Test, representing the next generation of point-of-need solutions for the management of infectious diseases and other personalized medicine applications.
www.microgembio.com/covid-19
Contact: Lianne Landers, Sr. Director of Corporate Communications
[email protected]
SOURCE Thomas Scientific
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article